Effects of matrix on plasma levels of EPA and DHA in dogs

EPA and DHA are often used in veterinary medicine due to their beneficial effects for several medical conditions such as osteoarthritis. EPA and DHA are administered to dogs through different matrices. The aim of the present study was to determine the effects on the plasma levels in dogs caused by v...

Full description

Bibliographic Details
Main Authors: Kay Goffin, Marc van Maris, Ronald J. Corbee
Format: Article
Language:English
Published: Cambridge University Press 2017-01-01
Series:Journal of Nutritional Science
Subjects:
Online Access:https://www.cambridge.org/core/product/identifier/S2048679017000301/type/journal_article
_version_ 1811155955393495040
author Kay Goffin
Marc van Maris
Ronald J. Corbee
author_facet Kay Goffin
Marc van Maris
Ronald J. Corbee
author_sort Kay Goffin
collection DOAJ
description EPA and DHA are often used in veterinary medicine due to their beneficial effects for several medical conditions such as osteoarthritis. EPA and DHA are administered to dogs through different matrices. The aim of the present study was to determine the effects on the plasma levels in dogs caused by various matrices for EPA and DHA administration. In this study, three different n-3 PUFA formulations were used: soft chew tablet (CCx); liquid fish oil (LFO); and enriched kibbles (EK). The formulations were administered single-dose and compared in a randomised, cross-over designed study with a 1-week wash-out period. Several variables were observed after the administration of these formulations in thirteen dogs: the NEFA plasma concentration, the AUC for 1 d (AUC0–24 h), and maximum plasma concentration for both EPA and DHA. All plasma fatty acid levels reached baseline levels within 72 h. CCx (median = 2·987) had a significantly lower AUC0–24 h for EPA compared with LFO (median = 5·647, P = 0·043) and EK (median = 5·119, P = 0·032) (F 2,22 = 4·637, P = 0·021). CCx (median = 2·471) AUC0–24 h for DHA was significantly lower compared with LFO (median = 4·837, Z = −2·56, P = 0·011) and EK (median = 4·413, Z = −2·59, P = 0·01). EPA and DHA plasma levels were affected by matrix, as with the CCx, the AUC0–24 h of EPA and DHA were both lower compared with LFO and EK. The effect of matrix on bioavailability is important for product development as well as for clinical trials studying effects of EPA and DHA.
first_indexed 2024-04-10T04:42:23Z
format Article
id doaj.art-ee76e9e2ca3048a8a0b7689b9a0ff5d6
institution Directory Open Access Journal
issn 2048-6790
language English
last_indexed 2024-04-10T04:42:23Z
publishDate 2017-01-01
publisher Cambridge University Press
record_format Article
series Journal of Nutritional Science
spelling doaj.art-ee76e9e2ca3048a8a0b7689b9a0ff5d62023-03-09T12:38:57ZengCambridge University PressJournal of Nutritional Science2048-67902017-01-01610.1017/jns.2017.30Effects of matrix on plasma levels of EPA and DHA in dogsKay Goffin0Marc van Maris1Ronald J. Corbee2Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 108, 3584 CM Utrecht, The NetherlandsAyanda Concordix AS, Brynsveien 11-13, N-0667 Oslo, NorwayDepartment of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 108, 3584 CM Utrecht, The NetherlandsEPA and DHA are often used in veterinary medicine due to their beneficial effects for several medical conditions such as osteoarthritis. EPA and DHA are administered to dogs through different matrices. The aim of the present study was to determine the effects on the plasma levels in dogs caused by various matrices for EPA and DHA administration. In this study, three different n-3 PUFA formulations were used: soft chew tablet (CCx); liquid fish oil (LFO); and enriched kibbles (EK). The formulations were administered single-dose and compared in a randomised, cross-over designed study with a 1-week wash-out period. Several variables were observed after the administration of these formulations in thirteen dogs: the NEFA plasma concentration, the AUC for 1 d (AUC0–24 h), and maximum plasma concentration for both EPA and DHA. All plasma fatty acid levels reached baseline levels within 72 h. CCx (median = 2·987) had a significantly lower AUC0–24 h for EPA compared with LFO (median = 5·647, P = 0·043) and EK (median = 5·119, P = 0·032) (F 2,22 = 4·637, P = 0·021). CCx (median = 2·471) AUC0–24 h for DHA was significantly lower compared with LFO (median = 4·837, Z = −2·56, P = 0·011) and EK (median = 4·413, Z = −2·59, P = 0·01). EPA and DHA plasma levels were affected by matrix, as with the CCx, the AUC0–24 h of EPA and DHA were both lower compared with LFO and EK. The effect of matrix on bioavailability is important for product development as well as for clinical trials studying effects of EPA and DHA.https://www.cambridge.org/core/product/identifier/S2048679017000301/type/journal_articleFatty acidsOsteoarthritisMicro-encapsulationEmulsions
spellingShingle Kay Goffin
Marc van Maris
Ronald J. Corbee
Effects of matrix on plasma levels of EPA and DHA in dogs
Journal of Nutritional Science
Fatty acids
Osteoarthritis
Micro-encapsulation
Emulsions
title Effects of matrix on plasma levels of EPA and DHA in dogs
title_full Effects of matrix on plasma levels of EPA and DHA in dogs
title_fullStr Effects of matrix on plasma levels of EPA and DHA in dogs
title_full_unstemmed Effects of matrix on plasma levels of EPA and DHA in dogs
title_short Effects of matrix on plasma levels of EPA and DHA in dogs
title_sort effects of matrix on plasma levels of epa and dha in dogs
topic Fatty acids
Osteoarthritis
Micro-encapsulation
Emulsions
url https://www.cambridge.org/core/product/identifier/S2048679017000301/type/journal_article
work_keys_str_mv AT kaygoffin effectsofmatrixonplasmalevelsofepaanddhaindogs
AT marcvanmaris effectsofmatrixonplasmalevelsofepaanddhaindogs
AT ronaldjcorbee effectsofmatrixonplasmalevelsofepaanddhaindogs